Case Studies

Challenge: Alacrita was asked to assess a novel mAB-based approach to suppressing cancer metastases. The client, a biotech incubator with rights to the project, was considering further investment,...

Challenge: Our client was a publicly-traded clinical-stage pharmaceutical company, which specialized in drug formulation and delivery technology innovation. Its lead development drug was an inhaled...

Challenge: A developer of live biotherapeutic products (LBP) derived from stool donations had a lead product in phase 2 clinical trials for metabolic pathology secondary to hepatic pathology. An...

Challenge: A generalist private equity firm was considering an investment in a computational chemistry company, and required an evaluation of the company’s software suite as part of its due diligence...

Challenge A company was developing a unique dengue vaccine which it planned to out-license to a Big Pharma partner. Alacrita was commissioned to provide business development support to identify a...

Challenge Our client, a mid-cap research-based pharmaceutical company, had enjoyed striking success with a rare disease product which had different market dynamics to the bulk of the company's...

Challenge: A European pharmaceutical company focussed on ophthalmic care was seeking Well Established Use (WEU) approval in Europe for a small molecule asset. The company commissioned Alacrita to...

Challenge: A research-focused biotech company developing a novel, first-in-class, next generation oral anticoagulant for the prevention of life-threatening thrombotic events asked Alacrita to...

Challenge: An in-silico drug discovery company requested an expert review of the robustness and potential positioning of a new kinase inhibitor in oncology and inflammatory disease. Alacrita was...

Challenge: A European investor required due diligence support to appraise the attractiveness of a series of potential investments. The technologies included a theranostic agent, a DNA damage response...

Challenge A preclinical-stage company developing an integrin-targeting oncology asset engaged Alacrita to quantify the value potential of its lead asset in pancreatic ductal adenocarcinoma (PDAC),...

Challenge: Our client was a European mid-size pharmaceutical company considering an investment in a clinical-stage company developing an asset for multiple indications associated with pre-term birth...